Mechanisms of Action of Phytoestrogens and Their Role in Familial Adenomatous Polyposis.

colorectal cancer estrogen receptor β familial adenomatous polyposis phytoestrogens

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
10 May 2024
Historique:
received: 04 04 2024
revised: 30 04 2024
accepted: 02 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Familial adenomatous polyposis (FAP) is a rare disease characterized by the development of adenomatous polyps in the colon and rectum already in adolescence. If left untreated, patients develop colorectal cancer (CRC) with a 100% probability. To date, the gold standard of FAP management is surgery, which is associated with morbidity and mortality. A chemopreventive agent capable of delaying, preventing and reversing the development of CRC has been sought. Several classes of drugs have been used but to date no chemopreventive drug has been found for the management of this disease. In recent years, the importance of estrogen receptors in FAP and CRC, particularly the β subtype, has emerged. Indeed, the expression of the latter is strongly reduced in adenomatous polyps and CRC and is inversely correlated with the aggressiveness of the disease. Since phytoestrogens have a high affinity for this receptor, they have been suggested for use as chemopreventive agents in FAP and CRC. A combination of phytoestrogens and insoluble fibres has proved particularly effective. In this review, the various mechanisms of action of phytoestrogens were analyzed and the effectiveness of using phytoestrogens as an effective chemopreventive strategy was discussed.

Identifiants

pubmed: 38794302
pii: pharmaceutics16050640
doi: 10.3390/pharmaceutics16050640
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Irene Falsetti (I)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy.

Gaia Palmini (G)

Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50129 Florence, Italy.

Teresa Iantomasi (T)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy.

Maria Luisa Brandi (ML)

Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50129 Florence, Italy.

Francesco Tonelli (F)

Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), 50129 Florence, Italy.

Classifications MeSH